We Apologies For Any Inconveniences As The Site Is Having Some Technical Changes Done With New Modules Coming Soon

BREAKING NEWS
Source: COVID-19 Research  Jul 18, 2020  2 years ago
COVID-19 Research: John Hopkins Researchers Use Infusion Of Regulatory T-Cells To Treat Severe COVID-19 Condition
COVID-19 Research: John Hopkins Researchers Use Infusion Of Regulatory T-Cells To Treat Severe COVID-19 Condition
Source: COVID-19 Research  Jul 18, 2020  2 years ago
COVID-19 Research: A new report by researchers from John Hopkins University School of Medicine suggests an infusion of cells that dampen the body's immune response might help individuals with severe cases of the new coronavirus recover more quickly.


 
In the report, two patients so sick with COVID-19 that they'd been put on a ventilator improved quickly when given an infusion of regulatory T-cells, which are cells that check the immune system and prevent it from overreacting to an infectious threat.
 
The report was published in the journal: the Annals of Internal Medicine. https://www.acpjournals.org/doi/10.7326/L20-0681
 
Dr Douglas Gladstone, a hematologist at the Johns Hopkins Kimmel Cancer Center in Baltimore explained, ”Some patients' immune systems respond to COVID-19 so strongly that they wind up with pneumonia and other health problems caused by severe inflammation. What's a little bit unique to COVID is that these cells that dampen the immune system, called T regulatory cells, are afflicted by coronavirus. Their natural dampening response is blunted because they lack 'T regs.' The immune system is out of balance."
 
A possible way to counter this might be to treat people with fresh T reg cells from some other source, Gladstone and his colleagues figured.
 
Hence they obtained doses of T regulatory cells derived from umbilical cord blood by a biotech company called Cellenkos, and tried treating a pair of very sick COVID-19 patients with the cells.
 
The initial patient was a 69-year-old nursing home resident who had to be put on a ventilator after a week in the hospital, while the second was a 47-year-old man who needed ventilation after just two days of hospitalization.
 
Dr Gladstone said, "The ventilatory machine was basically maxed out for both patients, and both were in shock. Their inflammatory system was so revved up they were on medications to artificially raise their blood pressure.”
 
The researchers  infused the T reg cells into the two patients via IV two to three times, with a few days separating each dose.
 
Dr Gladstone added, "It turned out their inflammation markers dropped very quickly after the infusion of these cells."
 
Both the patients were able to stop taking the drugs to raise their blood pressure within about two days, and both came off ventilation in a matter of weeks.
 
The regulatory T cells worked so well that researchers now want to pursue a follow-up trial involving 45 people treated with one of two doses of T reg cells or a placebo, Gladstone said.
 
The positive result from that trial could lead to an even larger trial involving more hospitals. The hope is to have a treatment that helps patients bounce back quickly, reducing their long-term recovery time.
 
Dr Gladstone said, "Currently people can be intubated for 30 days and survive, but gee whiz, being intubated for 30 days, the recovery from that takes a long, long time. We want to take a bite out of it."
 
This type of treatment makes sense given what doctors know about how COVID-19 affects the immune system and harms the body, said Dr Greg Poland, director of the Vaccine Research Group at the Mayo Clinic in Rochester, Minnesota.
 
Dr Poland added, "You do see inflammatory markers pretty rapidly drop, and the concern in the more severe level of COVID-19 is it may be the body's overreaction, the so-called cytokine storm, that is enough to tip over into being pathologic."
 
However the only problem Dr Poland sees is where this therapy might fit in with all of the other COVID-19 research that's ongoing.
 
Dr Poland explained, "The hard part is there's a limited number of COVID patients that are in hospitals, because most won't end up in hospitals, and that are sick enough to be in these kind of trials. You wouldn't do this with somebody who had mild or even moderate disease."
 
For more on COVID-19 Research, keep on logging to Thailand Medical News.
 

MOST READ

Feb 05, 2020  2 years ago
Source : Thailand Medical news